Quick Answer
DiaMedica Therapeutics Inc. reported Research And Development Expense of $24.61 million for the year ending 2025.
- DiaMedica Therapeutics Inc. showed an increase of +29.2% in Research And Development Expense from 2024 to 2025.
- This data is from DiaMedica Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $791.0 thousand | Q2 2018: $1.07 million | Q3 2018: $1.21 million | Q1 2019: $2.61 million | Q2 2019: $1.87 million | Q3 2019: $1.62 million | Q1 2020: $1.35 million | Q2 2020: $1.60 million | Q3 2020: $2.16 million | Q1 2021: $2.41 million | Q2 2021: $2.16 million | Q3 2021: $2.33 million | Q1 2022: $1.97 million | Q2 2022: $1.96 million | Q3 2022: $1.64 million | Q1 2023: $3.62 million | Q2 2023: $2.54 million | Q3 2023: $3.27 million | Q1 2024: $3.68 million | Q2 2024: $3.93 million | Q3 2024: $4.98 million | Q1 2025: $5.66 million | Q2 2025: $5.82 million | Q3 2025: $6.44 million.
- Over the full 9 years of available data (2017 to 2025), DiaMedica Therapeutics Inc.'s Research And Development Expense has grown by 667.7%.
- Historical annual values: Fiscal year 2025: $24.61 million | Fiscal year 2024: $19.06 million | Fiscal year 2023: $13.11 million | Fiscal year 2022: $7.84 million | Fiscal year 2021: $8.77 million | Fiscal year 2020: $8.21 million | Fiscal year 2019: $7.90 million | Fiscal year 2018: $4.52 million | Fiscal year 2017: $3.21 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: